Comparative Pharmacology
Head-to-head clinical analysis: H CORT versus STERANE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: H CORT versus STERANE.
H-CORT vs STERANE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H-CORT (hydrocortisone) is a corticosteroid with glucocorticoid and mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory and immunosuppressive effects by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production.
Sterane (prednisolone) is a glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and decreasing cytokine production.
Intravenous: 100-250 mg as a single dose or up to 1 gram daily for acute conditions. Oral: 20-30 mg daily in divided doses. Maintenance: 5-20 mg daily.
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours. Clinical context: Short half-life requires q4-6h dosing; duration may be prolonged in hepatic impairment.
Terminal elimination half-life is approximately 2.5 hours (range 2-3 hours) in adults with normal renal function; clinically, this supports twice-daily dosing
Renal: ~80% as metabolites, ~5% unchanged; biliary/fecal: ~15%
Renal (approximately 70% as unchanged drug and glucuronide conjugate), biliary/fecal (approximately 30%)
Category C
Category C
Corticosteroid
Corticosteroid